Advanced Freeze Dryer

The Food and Drug Administration is preparing to acquire an advanced freeze dryer to enhance its research and regulatory capabilities for lyophilized drug products, which comprise approximately 70 percent of FDA-approved antibiotics and the majority of injectable medications. This equipment will support critical activities such as the evaluation of generic and new drug applications, facility inspections, staff training, and the development of science-based regulatory guidance. Equipped with advanced process monitoring and control features, the lyophilizer will enable the FDA to assess manufacturing quality more precisely and establish robust standards that ensure the safety, efficacy, and consistency of lyophilized drugs, including complex generics and biologics essential to public health. The acquisition is part of a broader effort to strengthen the FDA’s infrastructure for evaluating high-priority drug products and maintaining global leadership in pharmaceutical regulation. The device will be used to investigate manufacturing variability, support quality-by-design initiatives, and improve the agency’s ability to respond to emerging challenges in drug production. The contract opportunity is forecasted under NAICS code 333415, with the FDA’s Center for Drug Evaluation and Research serving as the primary point of contact, and acquisition inquiries should be directed to cderacquisitions@fda.hhs.gov. Although the contracting officer details remain pending, the project reflects the FDA’s strategic commitment to safeguarding the drug supply chain through cutting-edge scientific tools and regulatory innovation.